The optimized monoclonal antibody to a tissue factor course inhibitor (TFPI)

Japanese Patent JP6025570

B2

Monoclonal antibodies to human tissue factor pathway inhibitor (TFPI) are provided. Further provided are the isolated nucleic acid molecules encoding the same. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treatment of genetic and acquired deficiencies or defects in coagulations such as hemophilia A and B are also described. Also described are methods for shortening the bleeding time by administering an anti-TFPI monoclonal antibody to a patient in need thereof. Methods for producing a monoclonal antibody that binds human TFPI according to the present invention are also provided. In some embodiments, the monoclonal antibodies to TFPI provided have been optimized, for example to have increased affinity or increased functional activity.

JP2004229642	PROTEIN AND DNA ENCODING THE SAME
JP4279289	Lymphocyte Chemistry Attractors and Their Uses

One Juoji
Junlian Pan
Joanna Guldozinska
Christian Fozmeier
Yang Thebe
Jörg Birkenfeld
Nina Vobsto
Zimone Bruckner
Suzanne Steinich
Peter Scholz

JP2012556192A

November 16, 2016

March 01, 2011

Click for automatic bibliography generation  

Bayer HealthCare LLC

C07K16/18; A61K39/395; A61P7/04; A61P43/00

WO2010017196A1

J. Mol. Biol., 1995, 254(3), pp.392-403

Makoto Ono
Kenkyo Kanayama
Mitsuaki Tsubokura
Kazuki Shigemori
Kenji Ando
Hidehiko Ichikawa
Takahiro Aoki
Yoshie Sakurada
Yousuke Kawasaki
Toshikazu Imato
Takuya Gomibuchi
Yoshikazu Iwase
Yasufumi Shiroyama

Previous Patent: A front fraise and its use

Next Patent: PROTECTION OF COATING JIG